GetTopicDetailResponse(id=7dc82898075, topicName=免疫化療, introduction=免疫化療, content=null, image=null, comments=0, allHits=1243, url=https://h5.medsci.cn/topic?id=28980, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=37228, tagList=[TagDto(tagId=37228, tagName=免疫化療)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2276219, encodeId=52d922e62199a, content=<a href='/topic/show?id=7dc82898075' target=_blank style='color:#2F92EE;'>#免疫化療#</a> <a href='/topic/show?id=ca679389279' target=_blank style='color:#2F92EE;'>#邊緣區(qū)淋巴瘤#</a>, objectTitle=【Blood】邊緣區(qū)淋巴瘤的治療, objectType=article, longId=890232, objectId=263e8902322f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241212/1733998939042_8538692.png, objectUrl=/article/show_article.do?id=263e8902322f, replyNumber=0, likeNumber=15, createdTime=2025-08-06, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=263e8902322f, moduleTitle=【Blood】邊緣區(qū)淋巴瘤的治療, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=263e8902322f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2221197, encodeId=34a4222119e6a, content=<a href='/topic/show?id=7dc82898075' target=_blank style='color:#2F92EE;'>#免疫化療#</a> <a href='/topic/show?id=e891531944f' target=_blank style='color:#2F92EE;'>#惰性非霍奇金淋巴瘤#</a> <a href='/topic/show?id=7044118063c6' target=_blank style='color:#2F92EE;'>#Copanlisib#</a>, objectTitle=基于copanlisib和利妥昔單抗的免疫化療對復發(fā)惰性B細胞淋巴瘤的3期研究：CHRONOS-4研究, objectType=article, longId=838997, objectId=921f83899e47, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240703/1719981273634_5579292.jpg, objectUrl=/article/show_article.do?id=921f83899e47, replyNumber=0, likeNumber=227, createdTime=2024-08-18, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=921f83899e47, moduleTitle=基于copanlisib和利妥昔單抗的免疫化療對復發(fā)惰性B細胞淋巴瘤的3期研究：CHRONOS-4研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=921f83899e47)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2180343, encodeId=e7462180343d6, content=<a href='/topic/show?id=bde45355068' target=_blank style='color:#2F92EE;'>#慢性淋巴細胞白血病#</a> <a href='/topic/show?id=a649121941c' target=_blank style='color:#2F92EE;'>#MRD#</a> <a href='/topic/show?id=7dc82898075' target=_blank style='color:#2F92EE;'>#免疫化療#</a>, objectTitle=【ASH繼續(xù)教育】CLL的MRD驅(qū)動治療：MRD的定義、檢測方法及對長期生存的影響, objectType=article, longId=808482, objectId=a9c580848235, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-staff-meeting-GXNVP9J.jpg, objectUrl=/article/show_article.do?id=a9c580848235, replyNumber=0, likeNumber=141, createdTime=2024-01-09, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=a9c580848235, moduleTitle=【ASH繼續(xù)教育】CLL的MRD驅(qū)動治療：MRD的定義、檢測方法及對長期生存的影響, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=a9c580848235)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯話題小助手
2020-05-29
